| Trial | DASL-HiCaP |
|---|---|
| Cancer Type | Prostate Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer |
DASL-HiCaP
Posted in .